Viral hepatitis causing concomitant acute pancreatitis is a rare entity and outcomes vary depending on the type of hepatitis virus.
All articles by Virginia A. Schad, PharmD, RPh
Because after hepatitis B viral suppression the cause and intervention for elevated alanine aminotransferase is somewhat unknown, investigators conducted a real-world study.
Lenvervimab was well tolerated and reduced levels of HBsAg to below undetectable levels for up to 1 month in patients with chronic HBV infection.
Patients with HCV infection should receive DAA therapy even if they have alcohol use disorder, diabetes, cirrhosis, or hepatic encephalopathy.
HBsAg, interferon inducible protein-10, and hepatitis B core related antigen serum levels can be useful for the decisions and management of treatment discontinuation in non-cirrhotic white patients with HBeAg-negative chronic hepatitis B.
As emergency departments (EDs) are critical settings for hepatitis C care in the United States, investigators evaluated trends and characteristics of hepatitis C-associated ED visits from 2006 to 2014.
In a small patient cohort, researchers found that heart transplantation from donors who were hepatitis C virus-positive to recipients without the virus were successful.
In China, researchers investigate the sustained virologic response and safety profile of coblopasvir plus sofosbuvir taken once daily for 12 weeks among patients with HCV genotypes 1, 2, 3, or 6 infections, including individuals with compensated cirrhosis.
Using data from an Egyptian cohort, investigators sought to determine the safety and efficacy of adding epigallocatechin gallate to sofosbuvir plus daclatasvir with or without ribavirin to treat patients with chronic hepatitis C virus.
As direct-acting antiviral (DAA) treatment can lead to HBV re-activation, testing for HBV DNA along with anti-HBc antibodies in men who have sex with men and people who use drugs co-infected with hepatitis C virus is warranted prior to DAA-treatment.